Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris : Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Candida auris isolates exhibit elevated amphotericin B (AMB) minimum inhibitory concentrations (MICs). As liposomal AMB (L-AMB) can be safely administered at high doses, we explored L-AMB pharmacodynamics against C. auris isolates in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) dilution model.
METHODS: Four C. auris isolates with Clinical and Laboratory Standards Institute (CLSI) AMB MICs = 0.5-2 mg/L were tested in an in vitro PK/PD model simulating L-AMB pharmacokinetics. The in vitro model was validated using a Candida albicans isolate tested in animals. The peak concentration (Cmax)/MIC versus log10 colony-forming units (CFU)/mL reduction from the initial inoculum was analyzed with the sigmoidal model with variable slope (Emax model). Monte Carlo analysis was performed for the standard (3 mg/kg) and higher (5 mg/kg) L-AMB doses.
RESULTS: The in vitro PK/PD relationship Cmax/MIC versus log10 CFU/mL reduction followed a sigmoidal pattern (R2 = 0.91 for C. albicans, R2 = 0.86 for C. auris). The Cmax/MIC associated with stasis was 2.1 for C. albicans and 9 for C. auris. The probability of target attainment was >95% with 3 mg/kg for wild-type C. albicans isolates with MIC ≤2 mg/L and C. auris isolates with MIC ≤1 mg/L whereas 5 mg/kg L-AMB is needed for C. auris isolates with MIC 2 mg/L.
CONCLUSIONS: L-AMB was 4-fold less active against C. auris than C. albicans. Candida auris isolates with CLSI MIC 2 mg/L would require a higher L-AMB dose.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:229 |
---|---|
Enthalten in: |
The Journal of infectious diseases - 229(2024), 2 vom: 14. Feb., Seite 599-607 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Beredaki, Maria-Ioanna [VerfasserIn] |
---|
Links: |
---|
Themen: |
7XU7A7DROE |
---|
Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/infdis/jiad583 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365999784 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM365999784 | ||
003 | DE-627 | ||
005 | 20240219231935.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231227s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/infdis/jiad583 |2 doi | |
028 | 5 | 2 | |a pubmed24n1299.xml |
035 | |a (DE-627)NLM365999784 | ||
035 | |a (NLM)38109276 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Beredaki, Maria-Ioanna |e verfasserin |4 aut | |
245 | 1 | 0 | |a Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris |b Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.02.2024 | ||
500 | |a Date Revised 19.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
520 | |a BACKGROUND: Candida auris isolates exhibit elevated amphotericin B (AMB) minimum inhibitory concentrations (MICs). As liposomal AMB (L-AMB) can be safely administered at high doses, we explored L-AMB pharmacodynamics against C. auris isolates in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) dilution model | ||
520 | |a METHODS: Four C. auris isolates with Clinical and Laboratory Standards Institute (CLSI) AMB MICs = 0.5-2 mg/L were tested in an in vitro PK/PD model simulating L-AMB pharmacokinetics. The in vitro model was validated using a Candida albicans isolate tested in animals. The peak concentration (Cmax)/MIC versus log10 colony-forming units (CFU)/mL reduction from the initial inoculum was analyzed with the sigmoidal model with variable slope (Emax model). Monte Carlo analysis was performed for the standard (3 mg/kg) and higher (5 mg/kg) L-AMB doses | ||
520 | |a RESULTS: The in vitro PK/PD relationship Cmax/MIC versus log10 CFU/mL reduction followed a sigmoidal pattern (R2 = 0.91 for C. albicans, R2 = 0.86 for C. auris). The Cmax/MIC associated with stasis was 2.1 for C. albicans and 9 for C. auris. The probability of target attainment was >95% with 3 mg/kg for wild-type C. albicans isolates with MIC ≤2 mg/L and C. auris isolates with MIC ≤1 mg/L whereas 5 mg/kg L-AMB is needed for C. auris isolates with MIC 2 mg/L | ||
520 | |a CONCLUSIONS: L-AMB was 4-fold less active against C. auris than C. albicans. Candida auris isolates with CLSI MIC 2 mg/L would require a higher L-AMB dose | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Candida auris | |
650 | 4 | |a liposomal amphotericin B | |
650 | 4 | |a optimal dose | |
650 | 4 | |a pharmacokinetics/pharmacodynamics | |
650 | 7 | |a liposomal amphotericin B |2 NLM | |
650 | 7 | |a Amphotericin B |2 NLM | |
650 | 7 | |a 7XU7A7DROE |2 NLM | |
650 | 7 | |a Antifungal Agents |2 NLM | |
700 | 1 | |a Sanidopoulos, Ioannis |e verfasserin |4 aut | |
700 | 1 | |a Pournaras, Spyros |e verfasserin |4 aut | |
700 | 1 | |a Meletiadis, Joseph |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 229(2024), 2 vom: 14. Feb., Seite 599-607 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
773 | 1 | 8 | |g volume:229 |g year:2024 |g number:2 |g day:14 |g month:02 |g pages:599-607 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad583 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 229 |j 2024 |e 2 |b 14 |c 02 |h 599-607 |